![Mayoly Spindler enters exclusive negotiations to acquire IPSEN's CHC branch - MAYOLY SPINDLER laboratoire indépendant français Mayoly Spindler enters exclusive negotiations to acquire IPSEN's CHC branch - MAYOLY SPINDLER laboratoire indépendant français](https://www.mayoly-spindler.fr/wp-content/uploads/2022/02/LogoSunrise3.png)
Mayoly Spindler enters exclusive negotiations to acquire IPSEN's CHC branch - MAYOLY SPINDLER laboratoire indépendant français
![Exterior view of the headquarters building of Ipsen, a French pharmaceutical group, Boulogne-Billancourt, France Stock Photo - Alamy Exterior view of the headquarters building of Ipsen, a French pharmaceutical group, Boulogne-Billancourt, France Stock Photo - Alamy](https://c8.alamy.com/comp/2F5WC3E/exterior-view-of-the-headquarters-building-of-ipsen-a-french-pharmaceutical-group-boulogne-billancourt-france-2F5WC3E.jpg)
Exterior view of the headquarters building of Ipsen, a French pharmaceutical group, Boulogne-Billancourt, France Stock Photo - Alamy
![Ipsen finalizes purchase of Albireo Pharma to strengthen its rare disease portfolio | HealthCare Middle East & Africa Magazine Ipsen finalizes purchase of Albireo Pharma to strengthen its rare disease portfolio | HealthCare Middle East & Africa Magazine](https://www.healthcaremea.com/wp-content/uploads/2023/01/Ipsen.jpg)
Ipsen finalizes purchase of Albireo Pharma to strengthen its rare disease portfolio | HealthCare Middle East & Africa Magazine
![Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire](https://mms.businesswire.com/media/20211017005063/en/1228937/23/2560px-Ipsen_logo.svg.jpg)